This study also provides the rationale for testing of this combination immunotherapy approach in the clinic, potentially in tumor types that do not respond to ICB and are characterized by high levels of collagen, TGF-β, or tumor-infiltrating CD163+ M2 macrophages. The gene discussed is TGFB1; the disease is neoplasm.